Treatment for glioblastoma (GBM)
Intended for US audiences only.

Mechanism of action

Optune delivers TTFields to selectively disrupt mitosis1,2

Metaphase (A)1

Metaphase (A)
  • Impair microtubule assembly

Anaphase (B)3

Anaphase (B)
  • Impede midline localization of cytokinetic band
  • Induce cytoplasmic blebbing and mitotic failure
  • Cause asymmetric chromosome segregation

Telophase (C)1

Telophase (C)
  • Induce intracellular dielectrophoresis of macromolecules and organelles

Learn about TTFields mechanism of action

TTFields, tumor treating fields.

References: 1. Gutin PH, Wong ET. Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality. Am Soc Clin Oncol Educ Book. 2012:126-131. 2. Kirson ED, Dbalý V, Tovarys F, et al. Proc Natl Acad Sci USA. 2007:104(24):1­0­1­5­2­-­1­0­1­5­7. 3. Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor Treating Fields perturb the localization of septins and cause aberrant mitotic exit. PLoS ONE. 2015. 10(5): e0125269. doi:10.1371/journal.pone.0125269.

Inovitro Video

Learn more about the Inovitro system.

Watch video

Inovitro™ research

Find out about TTFields preclinical laboratory research.

Learn more

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).